{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:20:03Z","timestamp":1767968403317,"version":"3.49.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Interleukin-35 (IL-35) has been reported to inhibit the production of interleukin-17 (IL-17) as a means of preventing arthritis and other inflammatory diseases. We previously showed that treatment of<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected mice with anti-IL-17 antibody at the time of infection prevented the development of arthritis. The anti-IL-17 antibody-treated mice lacked the extensive tissue damage, such as bone and cartilage erosion, that occurred in the tibiotarsal joints of untreated<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected control mice. We hypothesized that IL-35 would reduce the severity of arthritis by suppressing the production of IL-17 in<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected mice. Here, we show that administration of recombinant IL-35 (rIL-35) to<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected mice augments the development of severe arthritis compared to the results seen with untreated control mice.<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected mice treated with rIL-35 had significantly (<jats:italic>P<\/jats:italic>&lt; 0.05) greater hind paw swelling and histopathological changes from day 4 through day 10 than non-rIL-35-treated<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-vaccinated and -infected mice. In addition, the treatment with IL-35 only slightly decreased the production of IL-17 in<jats:named-content content-type=\"genus-species\">Borrelia<\/jats:named-content>-primed immune cells and did not prevent the development of borreliacidal antibody. Our data do not support a role for IL-35 as a potential therapeutic agent to reduce inflammation in Lyme arthritis.<\/jats:p>","DOI":"10.1128\/cvi.00052-11","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T05:26:44Z","timestamp":1306387604000},"page":"1125-1132","source":"Crossref","is-referenced-by-count":37,"title":["Interleukin-35 Enhances Lyme Arthritis in<i>Borrelia<\/i>-Vaccinated and -Infected Mice"],"prefix":"10.1128","volume":"18","author":[{"given":"Joseph","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean T.","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Callister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald F.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2011,5,25]]},"reference":[{"key":"key20180919073521_B1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/CVI.13.2.289-296.2006","article-title":"Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice","volume":"13","author":"Amlong","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073521_B2","first-page":"22","article-title":"Lyme borreliosis in the laboratory mouse","volume":"3","author":"Barthold","year":"1996","journal-title":"J. Spirochetal Tick-Borne Dis."},{"key":"key20180919073521_B3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4269\/ajtmh.1992.47.605","article-title":"Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency","volume":"47","author":"Barthold","year":"1992","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"key20180919073521_B4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal development pathways for the generation of pathogenic effector Th17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"key20180919073521_B5","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/IAI.67.7.3329-3333.1999","article-title":"Experimental Lyme arthritis in the absence of interleukin-4 or gamma interferon","volume":"67","author":"Brown","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073521_B6","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1128\/IAI.67.4.1967-1973.1999","article-title":"Genetic control of experimental Lyme arthritis in the absence of specific immunity","volume":"67","author":"Brown","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073521_B7","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.71.6.3437-3442.2003","article-title":"Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi","volume":"71","author":"Burchill","year":"2003","journal-title":"Infect. Immun."},{"key":"key20180919073521_B8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/CDLI.3.4.399-402.1996","article-title":"Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a \u201cgold standard\u201d?","volume":"3","author":"Callister","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073521_B9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1529-0131(199909)42:9<1813::AID-ANR4>3.0.CO;2-0","article-title":"Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi","volume":"42","author":"Chen","year":"1999","journal-title":"Arthritis Rheum."},{"key":"key20180919073521_B10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CDLI.10.1.44-52.2003","article-title":"Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor alpha","volume":"10","author":"Christopherson","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073521_B11","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/art.23972","article-title":"Borrelia burgdorferi NapA-driven Th17 cell inflammation in Lyme arthritis","volume":"58","author":"Codolo","year":"2008","journal-title":"Arthritis Rheum."},{"key":"key20180919073521_B12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"key20180919073521_B13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/IAI.68.2.658-663.2000","article-title":"Occurrence of severe destructive Lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi","volume":"68","author":"Croke","year":"2000","journal-title":"Infect. Immun."},{"key":"key20180919073521_B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells: adversaries and collaborators","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073521_B15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaut.2004.06.005","article-title":"Molecular characterization of the OspA (161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato","volume":"23","author":"Drouin","year":"2004","journal-title":"J. Autoimmun."},{"key":"key20180919073521_B16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.160.2.1022","article-title":"T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis","volume":"160","author":"Gross","year":"1998","journal-title":"J. Immunol."},{"key":"key20180919073521_B17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.281.5377.703","article-title":"Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis","volume":"281","author":"Gross","year":"1998","journal-title":"Science"},{"key":"key20180919073521_B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000213069","article-title":"Epidemiology of Lyme borreliosis","volume":"37","author":"Hub\u00e1lek","year":"2009","journal-title":"Curr. Probl. Dermatol."},{"key":"key20180919073521_B19","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4049\/jimmunol.165.11.6107","article-title":"Microbial lipopeptides induce the production of IL-17 in Th cells","volume":"165","author":"Infante-Duarte","year":"2000","journal-title":"J. Immunol."},{"key":"key20180919073521_B20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1574-695X.2006.00210.x","article-title":"Borrelia burgdorferi potently activates bone marrow-derived conventional dendritic cells for production of IL-23 required for IL-17 release by T cells","volume":"49","author":"Knauer","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"key20180919073521_B21","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.4049\/jimmunol.0902739","article-title":"IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10","volume":"184","author":"Kochetkova","year":"2010","journal-title":"J. Immunol."},{"key":"key20180919073521_B22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/CVI.00129-08","article-title":"Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species","volume":"15","author":"Kotloski","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073521_B23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00373-08","article-title":"Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease","volume":"16","author":"LaFleur","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073521_B24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1084\/jem.180.6.2069","article-title":"The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis","volume":"180","author":"Lengl-Janssen","year":"1994","journal-title":"J. Exp. Med."},{"key":"key20180919073521_B25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CDLI.1.1.44-50.1994","article-title":"Detection of borreliacidal antibody by using acridine orange and flow cytometry","volume":"1","author":"Lim","year":"1994","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073521_B26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/IAI.63.4.1400-1408.1995","article-title":"Borrelia burgdorferi-specific T lymphocytes induce severe destructive Lyme arthritis","volume":"63","author":"Lim","year":"1995","journal-title":"Infect. Immun."},{"key":"key20180919073521_B27","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1128\/IAI.63.12.4818-4825.1995","article-title":"Involvement of CD4+ T lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamsters","volume":"63","author":"Lim","year":"1995","journal-title":"Infect. Immun."},{"key":"key20180919073521_B28","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.4049\/jimmunol.164.12.6096","article-title":"Cutting edge: T cell-mediated pathology in murine Lyme borreliosis","volume":"164","author":"McKisic","year":"2000","journal-title":"J. Immunol."},{"key":"key20180919073521_B29","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.4049\/jimmunol.158.10.4838","article-title":"Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils","volume":"158","author":"Morrison","year":"1997","journal-title":"J. Immunol."},{"key":"key20180919073521_B30","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakaez","year":"2003","journal-title":"J. Immunol."},{"key":"key20180919073521_B31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/CDLI.11.6.1075-1084.2004","article-title":"Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody","volume":"11","author":"Nardelli","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073521_B32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1128\/CDLI.12.6.786-792.2005","article-title":"CD4+ CD25+ T cells prevent arthritis associated with Borrelia vaccination and infection","volume":"12","author":"Nardelli","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073521_B33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1574-695X.2008.00431.x","article-title":"Role of IL-17, transforming growth factor-beta, and IL-6 in the development of arthritis and production of anti-outer surface protein A borreliacidal antibodies in Borrelia-vaccinated and -challenged mice","volume":"53","author":"Nardelli","year":"2008","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"key20180919073521_B34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1574-695X.2010.00721.x","article-title":"Significant differences between the Borrelia-infection and Borrelia-vaccination and -infection models of Lyme arthritis in C3H\/HeN mice","volume":"60","author":"Nardelli","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"key20180919073521_B35","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"key20180919073521_B36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/eji.201040385","article-title":"Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism","volume":"41","author":"Oosting","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"key20180919073521_B37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM198303313081301","article-title":"The spirochetal etiology of Lyme disease","volume":"308","author":"Steere","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"key20180919073521_B38","first-page":"725","article-title":"The clinical evolution of Lyme arthritis. Ann","volume":"107","author":"Steere","year":"1987","journal-title":"Intern. Med."},{"key":"key20180919073521_B39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1574-695X.2007.00356.x","article-title":"T cell infiltration is associated with increased Lyme arthritis in TLR2\u2212\/\u2212 mice","volume":"52","author":"Wang","year":"2008","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"key20180919073521_B40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1084\/jem.174.3.593","article-title":"Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis","volume":"174","author":"Yssel","year":"1991","journal-title":"J. Exp. Med."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00052-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T02:22:00Z","timestamp":1686104520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00052-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,25]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,5]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/CVI.00052-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00052-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,25]]}}}